Cargando…

Preoperative Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Stage I-III Gastric Cancer Patients with a MGC Component

BACKGROUND: The preoperative platelet-to-lymphocyte ratio (PLR) evaluates the prognosis of gastric cancer patients. However, whether preoperative PLR may be used to evaluate the prognosis of mucinous gastric carcinoma (MGC) patients is poorly investigated. The present study evaluated the effect of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ziyu, Gao, Jialiang, Liu, Zhixin, Li, Chunfeng, Xue, Yingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112911/
https://www.ncbi.nlm.nih.gov/pubmed/33997045
http://dx.doi.org/10.1155/2021/9678363
_version_ 1783690761702735872
author Zhu, Ziyu
Gao, Jialiang
Liu, Zhixin
Li, Chunfeng
Xue, Yingwei
author_facet Zhu, Ziyu
Gao, Jialiang
Liu, Zhixin
Li, Chunfeng
Xue, Yingwei
author_sort Zhu, Ziyu
collection PubMed
description BACKGROUND: The preoperative platelet-to-lymphocyte ratio (PLR) evaluates the prognosis of gastric cancer patients. However, whether preoperative PLR may be used to evaluate the prognosis of mucinous gastric carcinoma (MGC) patients is poorly investigated. The present study evaluated the effect of preoperative PLR on overall survival in gastric cancer patients with a mucinous component. METHODS: A total of 336 MGC were enrolled in this study, and the characteristics of the tumor, including pathological features and clinical data, were retrospectively analyzed. RESULTS: A high PLR was associated with larger tumor size, advanced tumor invasion, lymph node metastasis, advanced TNM stage, tumor location, total gastrectomy, low hemoglobin level, low albumin level, high fibrinogen level, high platelet level, and high neutrophil-to-lymphocyte ratio (NLR, all P′s < 0.05). Multivariate analysis identified age (HR = 1.876; 95% CI 1.361-2.585, P < 0.001), TNM stage (HR = 2.350; 95% CI 1.216-4.542, P = 0.011), globulin (HR = 1.520; 95% CI 1.067-2.165, P = 0.020), total gastrectomy (HR = 0.537; 95% CI 0.373-0.772, P = 0.001), and PLR (HR = 1.582; 95% CI 1.066-2.348, P = 0.023) as independent prognostic factors for OS. CONCLUSION: Preoperative PLR is related to pathological features and may independently evaluate the survival of MGC. Therefore, preoperative PLR may help physicians develop treatment plans and evaluate survival in these patients.
format Online
Article
Text
id pubmed-8112911
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-81129112021-05-13 Preoperative Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Stage I-III Gastric Cancer Patients with a MGC Component Zhu, Ziyu Gao, Jialiang Liu, Zhixin Li, Chunfeng Xue, Yingwei Biomed Res Int Research Article BACKGROUND: The preoperative platelet-to-lymphocyte ratio (PLR) evaluates the prognosis of gastric cancer patients. However, whether preoperative PLR may be used to evaluate the prognosis of mucinous gastric carcinoma (MGC) patients is poorly investigated. The present study evaluated the effect of preoperative PLR on overall survival in gastric cancer patients with a mucinous component. METHODS: A total of 336 MGC were enrolled in this study, and the characteristics of the tumor, including pathological features and clinical data, were retrospectively analyzed. RESULTS: A high PLR was associated with larger tumor size, advanced tumor invasion, lymph node metastasis, advanced TNM stage, tumor location, total gastrectomy, low hemoglobin level, low albumin level, high fibrinogen level, high platelet level, and high neutrophil-to-lymphocyte ratio (NLR, all P′s < 0.05). Multivariate analysis identified age (HR = 1.876; 95% CI 1.361-2.585, P < 0.001), TNM stage (HR = 2.350; 95% CI 1.216-4.542, P = 0.011), globulin (HR = 1.520; 95% CI 1.067-2.165, P = 0.020), total gastrectomy (HR = 0.537; 95% CI 0.373-0.772, P = 0.001), and PLR (HR = 1.582; 95% CI 1.066-2.348, P = 0.023) as independent prognostic factors for OS. CONCLUSION: Preoperative PLR is related to pathological features and may independently evaluate the survival of MGC. Therefore, preoperative PLR may help physicians develop treatment plans and evaluate survival in these patients. Hindawi 2021-05-03 /pmc/articles/PMC8112911/ /pubmed/33997045 http://dx.doi.org/10.1155/2021/9678363 Text en Copyright © 2021 Ziyu Zhu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zhu, Ziyu
Gao, Jialiang
Liu, Zhixin
Li, Chunfeng
Xue, Yingwei
Preoperative Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Stage I-III Gastric Cancer Patients with a MGC Component
title Preoperative Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Stage I-III Gastric Cancer Patients with a MGC Component
title_full Preoperative Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Stage I-III Gastric Cancer Patients with a MGC Component
title_fullStr Preoperative Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Stage I-III Gastric Cancer Patients with a MGC Component
title_full_unstemmed Preoperative Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Stage I-III Gastric Cancer Patients with a MGC Component
title_short Preoperative Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Stage I-III Gastric Cancer Patients with a MGC Component
title_sort preoperative platelet-to-lymphocyte ratio (plr) for predicting the survival of stage i-iii gastric cancer patients with a mgc component
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112911/
https://www.ncbi.nlm.nih.gov/pubmed/33997045
http://dx.doi.org/10.1155/2021/9678363
work_keys_str_mv AT zhuziyu preoperativeplatelettolymphocyteratioplrforpredictingthesurvivalofstageiiiigastriccancerpatientswithamgccomponent
AT gaojialiang preoperativeplatelettolymphocyteratioplrforpredictingthesurvivalofstageiiiigastriccancerpatientswithamgccomponent
AT liuzhixin preoperativeplatelettolymphocyteratioplrforpredictingthesurvivalofstageiiiigastriccancerpatientswithamgccomponent
AT lichunfeng preoperativeplatelettolymphocyteratioplrforpredictingthesurvivalofstageiiiigastriccancerpatientswithamgccomponent
AT xueyingwei preoperativeplatelettolymphocyteratioplrforpredictingthesurvivalofstageiiiigastriccancerpatientswithamgccomponent